1. Home
  2. VIVS vs DCOY Comparison

VIVS vs DCOY Comparison

Compare VIVS & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

N/A

Current Price

$0.20

Market Cap

3.8M

Sector

Health Care

ML Signal

N/A

Logo Decoy Therapeutics Inc. Common Stock

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$1.56

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VIVS
DCOY
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.2M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
VIVS
DCOY
Price
$0.20
$1.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
587.7K
★ 4.1M
Earning Date
11-05-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $4,603,000.00
N/A
Revenue This Year
$228,144.28
N/A
Revenue Next Year
N/A
$20.42
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 8.82
N/A
52 Week Low
$0.19
$0.53
52 Week High
$3.54
$13.51

Technical Indicators

Market Signals
Indicator
VIVS
DCOY
Relative Strength Index (RSI) 28.24 29.82
Support Level N/A $0.61
Resistance Level $0.30 $3.29
Average True Range (ATR) 0.02 0.69
MACD 0.00 -0.10
Stochastic Oscillator 16.30 0.33

Price Performance

Historical Comparison
VIVS
DCOY

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Share on Social Networks: